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Epilepsy is one of the most common neurologic disorders in dogs and life-long treatment 
with antiepileptic drugs (AED) is frequently required. Adverse events of AED targeting the 
skin are only rarely reported in veterinary medicine and the true incidence and spectrum 
of cutaneous reactions in epileptic dogs remains unknown. In this study, we hypothe-
sized that cutaneous reactions commonly occur in epileptic dogs and are related to AED 
treatment. A retrospective case review of 185 dogs treated for epilepsy identified 20.0% 
with simultaneous appearance of dermatologic signs. In a subsequent prospective 
case investigation (n = 137), we identified newly appearing or distinct worsening of skin 
lesions following initiation of AED therapy in 10.9% of dogs treated for epilepsy (95% CI 
6.8–17.7%). Cutaneous lesions were classified as probably drug-induced in 40.0% of 
these cases. Patch testing and intradermal testing were further investigated as potential 
diagnostic methods to confirm AED hypersensitivity. They were of high specificity but 
sensitivity and positive predictive value appeared inappropriate to recommend their 
routine use in clinical practice.
Keywords: epilepsy, phenobarbital, antiepileptic drug, adverse reaction, dermatologic, skin, side effects, patch 
test
inTrODUcTiOn
Anticonvulsant agents are well known to cause adverse drug reactions (ADR) in dogs and cats, and 
ADRs are a major concern for owners of epileptic dogs (1, 2). However, in those species, effects, which 
are not immunologically mediated such as polyphagia, polydipsia/polyuria, sedation, and ataxia, or 
an activation of liver enzymes predominate (3, 4). There are only few case reports in the scientific 
literature regarding immune-mediated hypersensitivity reactions against antiepileptic treatment in 
animals including blood cell dyscrasias (5, 6), idiosyncratic hepatopathy (caused by zonisamide) 
(7, 8), or cutaneous disorders. Superficial necrolytic dermatitis (SND) or more appropriate metabolic 
epidermal necrosis (MEN) was described to appear after several months to years of phenobarbital 
(PB) therapy and evidence supported its origin as a hepatocutaneous syndrome (9, 10). Dermatologic 
signs have also been a concern in dogs treated with potassium bromide (panniculitis) (11, 12) and 
zonisamide (erythema multiforme) (13).
Adverse drug reactions are divided into two categories: type 1 ADRs are not immune mediated and 
attributed to physical or chemical properties of the agent or its metabolites. They are dose dependent 
and predictable. Type 2 ADRs are immune mediated, idiosyncratic, and occur unpredictably. The 
TaBle 1 | classification of skin lesions with the naranjo probability 
index.
Question Yes no Do not know
Are there previous conclusive reports on this 
reaction?
+1 −1 0
Did the adverse event appear after the suspected 
drug was administered?
+2 −1 0
Did the adverse reaction improve when the drug 
was discontinued or a specific antagonist was 
administered?
+1 0 0
Did the adverse reaction reappear when the drug 
was readministered?
+2 −1 0
Are there alternative causes (other than the drug) 
that could on their own have caused the reaction?
−1 +2 0
Did the reaction reappear when a placebo was 
given?
−1 +1 0
Was the drug detected in the blood (or other fluids) 
in concentrations known to be toxic?
+1 0 0
Was the reaction more severe when the dose 
was increased or less severe when the dose was 
decreased?
+1 0 0
Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure?
+1 0 0
Was the adverse event confirmed by any objective 
evidence?
+1 0 0
Assignment of probability scores: total score ≤0 = doubtful, 1–4 = possible, 
5–8 = probable, and ≥ 9 = definite (26).
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mechanism of this type of ADR is not completely understood 
(14, 15). It is presumed that all four main types of immune reac-
tion – as defined by Gell and Coombs – play a significant role in 
drug allergy (14). Manifestations of drug-induced allergic reac-
tions can affect numerous organ systems and lead to liver damage, 
lymphadenopathy, pneumonia, or hematologic abnormalities, 
although cutaneous manifestations are most common (16).
In human medicine, antiepileptic drugs (AEDs) are well 
known to cause cutaneous ADRs in about 3% of patients treated 
with an AED (17). These immune-mediated hypersensitivity 
reactions can range from more frequent mild urticarioid or 
maculopapular eruptions to severe systemic reactions such as 
Anticonvulsant Hypersensitivity Syndrome (AHS) (17–19). It 
is suggested that AHS is triggered by a delayed type immune 
reaction (Type 4), since drug-specific T-cells appear to play a 
significant role (20), but several other approaches are discussed 
to be involved in pathogenesis such as cohesive viral infections 
with human herpes virus Types 6 and 7 or cytomegalovirus (21, 
22). Furthermore, recent investigations indicate that genetic fac-
tors predispose to the development of an adverse reaction against 
AED (23), such as a genetically caused deficiency of detoxifying 
enzymes, which leads to an accumulation of toxic metabolites 
(19, 21, 22, 24). Management of ADRs in patients with epilepsy 
creates specific challenges as any change in AED treatment sched-
ule may increase the risk for seizure recurrence, cluster seizures, 
or status epilepticus. Patch testing (PT) and intradermal testing 
(IDT) have been introduced in human medical practice during 
the last decades in order to predict the probability of an ADR 
against AED (20, 21).
We hypothesized that cutaneous signs occur more commonly 
in dogs treated with AEDs than reported in scientific literature. 
So, the aim of this study was to evaluate the proportion of AED-
treated dogs that developed dermatologic signs and whether 
these signs are consistent with an ADR. A secondary goal was 
the investigation of PT and IDT as diagnostic methods.
MaTerials anD MeThODs
retrospective evaluation of adverse 
events
Medical records of epileptic dogs seen between 01/2007 and 
12/2012 were reviewed for documentation of adverse events after 
initiation of AEDs. Inclusion criteria were a clinical diagnosis 
of epilepsy (idiopathic or structural) according to published 
criteria (25), medical treatment with one or more AEDs, and at 
least one follow-up visit in the clinic at least 2 weeks after drug 
initiation. Exclusion criteria were presence of or strong suspicion 
for a systemic disease prior to initiation of AED therapy or 
simultaneous treatment with other drugs at the time of occur-
rence of adverse events. In total, 185 dogs were included. All data 
collected, including blood parameters (hematology, chemistry, 
liver function test), results of the clinical examination, as well as 
owner-reported adverse events, were reviewed. The records were 
particularly screened for appearance of adverse events after ini-
tiation of AED therapy such as polydipsia/polyuria, polyphagia, 
ataxia, sedation, gastrointestinal signs, pancreatitis, hepatopathy, 
hematologic changes, behavioral changes, respiratory signs, and 
in particular dermatologic abnormalities. Dermatologic signs 
were documented by clinicians as part of structurally conducted 
history and examination. Pancreatitis was assumed if specific 
canine pancreatic lipase was increased and additionally matching 
clinical signs and/or matching ultrasonographic findings were 
present. Hepatopathy was assumed if blood values (decreased 
albumin, decreased total protein, increased bilirubin, increased 
ammonia, and increased bile acids in liver function test) and 
clinical signs indicated it, confirmed by ultrasonographic find-
ings. Each adverse event that occurred after AED initiation was 
noted, regardless of how long after drug initiation it occurred 
or whether it resolved again during therapy. Furthermore, we 
attempted follow-up calls to the owners of the dogs with noted 
dermatologic signs in order to obtain further information about 
the causality between occurrence of dermatologic signs and AED 
therapy.
Then, each case of registered cutaneous signs was classified 
as a doubtful, possible, probable, or definite ADR, as defined by 
Naranjo et al. (26) (Table 1). The probability category was assigned 
from the total score as followed: <0/0 = doubtful, 1–4 = possible, 
5–8 = probable, 9/>9 = definite (26).
Prospective evaluation of cutaneous 
reactions
Dogs diagnosed with epilepsy (idiopathic or structural) and 
treated with AEDs between 01/2013 and 12/2014 were pro-
spectively included and monitored for any new appearance 
of cutaneous signs after initiation of AED. Whenever feasible, 
complete dermatologic examination was performed by an ECVD 
TaBle 2 | antiepileptic agents unsed in patch tests.
active substance Trade name concentration per pill (mg)
Phenobarbital Luminal Vet® 100
Potassium bromide Libromide® 325
Levetiracetam Keppra® 100
Gabapentin Gabapentin, 1A Pharma® 100
Zonisamide Zonegran® 50
TaBle 3 | evaluation of patch test sites.
– No visible reaction or irritation
1+ Mild erythema
2+ Moderate erythema
3+ Severe erythema
++ Erythema and induration or edema (papules)
+++ Erythema with vesiculation or more severe reactions
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diplomate or resident which routinely included detailed dermato-
logic history, visual inspection of the lesions, skin scrapings, and 
cytologic examination in order to describe the appeared lesions 
as precisely as possible and to exclude other potential causes 
such as ectoparasites and infections. Inclusion and exclusion 
criteria were identical to the ones described for the retrospective 
evaluation. Owners of dogs with dermatologic signs were asked 
to fill in a standardized questionnaire or alternatively answer a 
follow-up phone call. Based on this information, cutaneous signs 
were ranked using the Naranjo probability index as described for 
the retrospective data.
evaluation of Patch Test and intradermal Test
Dogs
Patch test (PT) and IDT were performed in six dogs with a clini-
cal diagnosis of epilepsy, which had developed skin lesions after 
initiation of PB monotherapy (four dogs) or combination therapy 
(two dogs).
Control Groups
Ten laboratory Beagle dogs (two males, eight females, median 
age 3.8 years; range: 2–4 years) that had never received any AED 
and therefore were most likely not sensitized to those allergens 
and seven dogs with a clinical diagnosis of idiopathic epilepsy 
(three males, four females, three Border collies, two Labrador 
Retrievers, one Beagle, and one German shepherd mix; median 
age: 2.5  years, range: 1.5–9  years) currently treated with PB 
monotherapy (2) or combination therapy [two PB/potassium 
bromide (KBr) and three PB/levetiracetam (LEV)] without any 
previous or current dermatologic signs.
In the laboratory Beagle dogs, the PT included PB, potas-
sium bromide, LEV, gabapentin, and zonisamide, and the IDT 
included PB and potassium bromide. The privately owned dogs 
were patch tested for those AEDs, which they currently received 
or had received previously. PB and, if the AED treatment included 
it, potassium bromide were additionally used in the IDT.
Patch Test
For the patch test, two different concentrations (5 and 10%) 
of petrolatum-solved agents were compounded for each AED 
(Table  2). Tablets were grounded with a tablet grinder to an 
instant powder, which was solved in petrolatum. Approximately 
0.2 cc of the prepared solutions were placed in Finn chambers of 
12 mm diameter. Pure petrolatum was used as negative control. 
The Finn chambers were placed firmly on the clipped skin on the 
lateral thorax and carefully fixed by surgical tape as described 
previously (27). The dogs wore a body suit for 48 h to prevent 
shifting of the chambers (27–29). After 48 h, the chambers were 
removed, and the skin reactions were evaluated as described 
previously (Table 3) (27).
Intradermal Test
Intradermal testing was performed with PB and potassium 
bromide. The corresponding amount of 200 mg effective agent 
was solved in 2 cc of sterile isotonic saline solution, resulting in a 
10% dilution. To detect the minimum drug dilution not trigger-
ing a positive reaction when injected into the skin of a healthy, 
non-sensitized dog, serial dilutions were prepared (10, 1, 0.1, and 
0.01%) and injected intradermally into the skin of a healthy labo-
ratory Beagle dog, which had never received any AEDs. Positive 
reactions were seen with the 10 and 1% dilution. Consequently, a 
0.1% dilution of both drugs was used subsequently in this study. 
An area of 20  cm ×  15  cm on the lateral thorax was clipped, 
and the injection sites were marked by an indelible felt pen. 
Approximately 0.05 cc of each solution as well as a positive (his-
tamine 1:100,000) and a negative control (sterile isotonic saline 
solution) were injected intradermally using an insulin syringe 
(0.33 mm × 12 mm) as previously described (30). After 15 and 
25 min, the skin reaction and diameter of the wheal at the drug 
injection site were compared to the negative and positive control 
and graded either negative (−) or positive as +, ++, or +++, 
depending on strength of reaction.
Sensitivity, specificity, and positive and negative predictive 
value of PT and IDT and their 95% confidence intervals were 
calculated.
This animal experiment was approved by the government, 
under the reference 55.2-1-54-2532-4-13. The laboratory dogs 
were housed according to the prescribed conditions of the 
German animal protection law. Epileptic dogs were privately 
owned patients of the clinic. All animal owners signed informed 
consent prior to study participation.
resUlTs
retrospective evaluation of adverse 
events
In total, 185 dogs (84.9% idiopathic epilepsy and 15.1% struc-
tural epilepsy) fulfilled the inclusion criteria. The 52.4% of the 
retrospective cases were treated with AED monotherapy [93 with 
PB, 3 with potassium bromide (KBr), and 1 with levetiracetam 
(LEV)] and 47.6% with a combination of AED (66 with PB/KBr, 
5 with PB/LEV, 10 with PB/KBr/LEV, 3 with PB/KBr/gabepentin, 
1 with PB/KBr/zonisamide, 1 with PB/zonisamide, 1 with PB/
KBr/LEV/zonisamide/pregabalin, and 1 with PB/pregabalin/
zonisamie/lacosamide).
TaBle 4 | adverse events during aeD therapy (n = 185).
Polyuria/
polydypsia
Polyphagia sedation ataxia gastro-intestinal 
disorders
Pancreatitis changes in 
behavior
respiratory 
signs
Dermatol. 
signs
hepatopathy
PB (n = 93) 15 19 16 15 4 3 5 0 17 3
KBr (n = 3) 0 0 0 1 0 0 0 0 0 0
LEV (n = 1) 0 1 0 0 0 0 0 0 1 0
PB + KBr (n = 66) 15 11 18 24 11 4 8 1 12 1
PB + LEV (n = 5) 1 2 5 3 0 0 0 0 1 0
PB + KBr + LEV (n = 10) 4 4 4 4 4 3 3 0 4 0
Other AED (n = 7) 1 1 1 3 2 0 0 1 2 0
Count 36 38 44 50 21 10 16 2 37 4
Percentage of all reviewed 
dogs (n = 185) in %
19.5 20.5 23.8 27.0 11.4 5.4 8.6 1.1 20.0 2.2
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Clinical signs that occurred after initiation of antiepileptic 
treatment and were considered adverse events are listed in Table 4. 
Most frequently noted were ataxia (27.1%), sedation (23.8%), and 
polyphagia (20.5%), while pancreatitis (5.4%) and hepatopathy 
(2.2%) were less frequently seen. Neutropenia occurred in six dogs 
(3.2%). Cutaneous signs were documented in 20.0% of the cases, 30 
of them diagnosed with idiopathic epilepsy. The dermatologic signs 
ranged from solely pruritus/alopecia (n = 23), skin lesions such as 
papules, pustules, or erythema (n = 13) to severe reactions such as 
epidermal necrosis (n = 1). In total, 26 owners were available for 
a detailed follow-up phone interview. These owner interrogations 
revealed that four dogs already had dermatologic signs before AED 
initiation and two owners could not surely remember whether the 
dermatologic signs occurred before or after AED therapy. Based on 
these information and on the clinical records, the Naranjo index 
(26) was used in order to classify the dermatologic signs as prob-
ably related to AED treatment in 2 dogs (5.4%), possible in 22 dogs 
(59.5%), and doubtful in 13 dogs (35.1%).
Prospective evaluation of cutaneous 
signs
Within this study part, 137 dogs (74.5% idiopathic epilepsy 
and 25.5% structural epilepsy) fulfilled the inclusion criteria. 
Of the 137 dogs, 10.9% (95% CI 6.8–17.7%, 15 dogs) presented 
with dermatologic signs of varying extent, which appeared after 
initiation of AED therapy. All of the dogs with dermatologic 
signs were diagnosed with idiopathic epilepsy except for one 
(P5) with ambiguous results in neurologic examination, which 
were not consistent with idiopathic epilepsy. Detailed owner 
interrogation revealed that three of the dogs already had mild 
dermatologic signs before onset of seizures which worsened after 
AED initiation (Table 5). All dogs were treated with PB. Twelve 
dogs received PB monotherapy, and three were treated with a PB 
combination therapy (PB/LEV, PB/KBr, PB/LEV/KBr). One of 
the dogs (P14) developed dermatologic signs shortly after ini-
tiation of LEV therapy, the others within days to several months 
after initiation of PB.
Nine dogs (P1, P3–6, P11–13, and P15) underwent complete 
dermatologic examination performed by a diplomate or resident 
ECVD, which included detailed dermatologic history and visual 
inspection of the lesions in all examined dogs as well as cytologic 
examination (n = 8), skin scrapings (n = 4), and bacteriological 
culture (n = 2). The remaining six dogs were examined by other 
clinicians, lacking further dermatologic tests. The cutaneous 
signs were described as severe with extensive erosions or epider-
mal necrosis leading to skin detachment in four dogs (P2, P5, 
P7, and P13). Eight dogs showed moderate signs, most notably 
papules, pustules, erythema, and crusty lesions, and three dogs 
showed mainly pruritus and/or alopecia. Particularly affected 
were the face, especially the periocular region, the mucocutane-
ous boundaries, the inguinal region, and the limbs (Table  5). 
Skin scrapings revealed Sarcoptes mites in dog P15. In this dog, 
antiparasitic therapy led to partial improvement of cutaneous 
signs. In the other 14 dogs, no other cause for the cutaneous 
lesions was identified. Skin biopsy was performed in one dog 
(P13) and indicated presence of erythema multiforme. AED 
therapy was withdrawn in seven cases (six dogs with PB and one 
dog with LEV). Cutaneous signs dissolved completely in five dogs 
within approximately 2 weeks (P2, P5, P11, P13, and P14). In one 
dog, a clear improvement, although no complete remission, was 
noticeable (P7), and in another dog (P1), appearance of severe 
seizures despite concomitant loading with KBr led to reinstitu-
tion of PB therapy after 2  weeks. Treatment for the cutaneous 
lesions included anti-inflammatory and/or antimicrobial topicals 
(n =  8), antiparasitic agents (n =  6), and short-term systemic 
prednisolone (n = 3). Treatment led to improvement of signs in 
all of the cases. However, this improvement was not complete 
and only temporary while topical or systemic anti-inflammatory 
medication was given. Based on the individual patient’s history, 
the examinations and the information obtained by standardized 
questionnaires, the Naranjo index was applied to classify the cuta-
neous signs as probably due to AED therapy in 40.0% (six dogs, 
all treated with PB monotherapy), and as possible (eight dogs; 
53.3%) or doubtful (one dog; 6.7%) in the remainder (Table 5). 
As an example, the skin lesions of dog P7 and P13 are depicted in 
Figures 1A,B and 2A,B. Both dogs had developed dermatologic 
signs several weeks after initiation of PB therapy and were both 
classified as probably drug-induced ADR.
evaluation of Patch Test and intradermal Test
Six dogs with cutaneous signs occurring under antiepileptic 
therapy (four PB monotherapy, one PB/LEV, and one PB/KBr) 
were tested with PT and IDT. Cutaneous signs were classified as 
probable due to AED therapy in two of these dogs, and as possible 
due to AEDs in the other four dogs. The clinical details of these 
TaBle 5 | Prospectively collected cases of skin lesions under antiepileptic treatment.
no. signalment antiepileptic 
therapy
adverse events Dermatologic 
signs prior to 
aeD therapy
Description of 
dermatologic signs after 
initiation of aeD
chronological 
appearance of 
dermatologic 
signs
Discontinuation  
of aeD therapy
classification 
of skin lesions 
according to 
naranjo et al.
Patch test intra-
dermal 
skin test
P 1 Mixed-breed, male, 
8a
PB Dermatologic 
signs
None Severe erosive perianal 
inflammation with purulent 
secretion
Several months 
after initiation of 
AED
Yes, but only for 
2 weeks, no improving of 
skin lesions during that 
period
Possible Positive (2+) Negative
P 2 Saluki, male-
neutered, 5a
PB Dermatologic 
signs
None Erosive-crusty dermatitis, 
generalized spread, 
especially in the face, at the 
testicles and oral mucosa
Several weeks 
after initiation of 
AED
Yes → complete 
remission within 
1–2 weeks
Probable Negative Negative
P 3 Mixed-breed, male, 
4a
PB later 
combination 
therapy PB/LEV
Dermatologic 
signs
None Pruritus, crusty lesions 
at the hind limbs and 
rhinarium
Weeks to months 
after PB initiation
No Possible Negative Positive 
(+ +)
P 4 Golden Retriever, 
female-neutered, 7a
PB Dermatologic 
signs
None Pruritus and alopecia at 
the limbs
Several months 
after initiation of 
AED
No Possible Negative Negative
P 5 Mixed-breed, male, 
3a
PB Dermatologic 
signs
None Erosive and crusty lesions 
perioccular, at the limbs 
and foot pads
Several days after 
initiation of AED
Immediately after 
appearance of 
dermatologic 
signs → complete 
remission within 
1–2 weeks
Probable No definite 
result (± )
Negative
P 6 Mixed-breed, male, 
5a
Combination 
therapy PB/KBr
Dermatologic 
signs
None Pruritus and alopecia at the 
limbs, crusty lesions at the 
ears and the inguinal region
Several months 
after initiation of 
AED
No Possible Negative Negative
P 7 Mixed-breed, male-
neutered, 8a
PB Dermatologic 
signs, changes in 
behavior
None Pruritus and crusty lesions 
around the eyes, at the 
ears, at the armpit area 
and breast
Several weeks 
after initiation of 
AED
Yes, for several weeks, 
improving of skin lesions 
during that period
Probable – –
P 8 Mixed-breed, male-
neutered, 2a
PB Dermatologic 
signs, ataxia
None Erosive and crusty lesions 
in the face and at the limbs
Several weeks 
after initiation of 
AED
No Probable – –
P 9 Hovawart, male-
neutered, 2a
PB Dermatologic 
signs
None Erosive lesions and 
discoloration of oral 
mucosa
Weeks to months 
after drug initiation
No Possible – –
P 10 Australian 
shepherd, male-
neutered, 8a
PB Dermatologic 
signs
None Generalized cornification 
of the skin, generalized 
spread papules and nodes
Several months 
after initiation of 
AED
No Possible – –
(Continued)
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no. signalment antiepileptic 
therapy
adverse events Dermatologic 
signs prior to 
aeD therapy
Description of 
dermatologic signs after 
initiation of aeD
chronological 
appearance of 
dermatologic 
signs
Discontinuation  
of aeD therapy
classification 
of skin lesions 
according to 
naranjo et al.
Patch test intra-
dermal 
skin test
P 11 Yorkshire terrier, 
male, 7a
PB Dermatologic 
signs
Moderate 
pruritus because 
of flea several 
months before
Severe pruritus and skin 
rash (pustules, papules, 
macule) in the armpit 
region and at the flanks
4 days after 
initiation of AED
Yes → complete 
remission within 1 week, 
never received PB again
Probable – –
P 12 French bulldog, 
female-neutered, 7a
PB Dermatologic 
signs: PU/PD, 
polyphagia
Mild allergic 
skin disease 
(pruritus) already 
before AED 
initiation
Aggravation of pruritus 
and appearance of crusty 
lesions at the rhinarium 
and hypotrichous areas 
and erythema at the limbs, 
perianal inflammation
Weeks to months 
after drug initiation
No Doubtful – –
P 13 Australian 
shepherd, male, 3a
PB Dermatologic 
signs
None Generalized spread, 
severe erosive, necrolytic 
dermatitis, especially at the 
mucocutaneous boundary, 
foot pads, testicles, 
perianal, and in the inguinal 
and armpit area
1–2 weeks 
after initiation of 
phenobarbital 
therapy
Immediately after 
appearance of 
dermatologic 
signs – >complete 
remission within 
1–2 weeks
Probable – –
P 14 American bulldog, 
male, 2a
PB/KBr Dermatologic 
signs, 
especially under 
levetiracetam
Mild pruritus 
already before 
AED therapy
Severe pruritus Days after initiation 
of LEV therapy
Immediately after 
appearance of 
dermatologic 
signs → complete 
remission within several 
days
Possible – –
LEV (for several 
days)
Later additionally 
imepitoin
P 15 Labrador retriever, 
male-neutered, 9a
PB Dermatologic 
signs, polyphagia
None Generalized spread, crusty, 
erosive lesions, alopecic 
areas, hypotrichosis at the 
limbs
Weeks after drug 
initiation
No, but improvement 
of signs under 
corticosteroids 
Possible – –
TaBle 5 | continued
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FigUre 3 | Dog P1 (mixed-breed, male, 8 years) developed a severe 
erosive perianal inflammation with purulent secretion after PB 
initiation (a). Patch test revealed a positive reaction to the 10% 
phenobarbital (arrowed) (B).
FigUre 4 | Dog P3 (mixed-breed, male, 4 years) developed pruritus 
and crusty lesions at the hind limbs and the rhinarium (a). Intradermal 
test revealed a positive reaction at the phenobarbital injection site (slim 
arrow), compared to positive control (big arrow) (B).
FigUre 2 | Dog P13 (australian shepherd, male, 3 years) developed a 
generalized, severe, erosive necrolytic dermatitis, especially at the 
oral mucosa (a), at the mucocutaneous junctions and the foot pads 
(B) 1–2 weeks after PB initiation; additionally affected were the 
testicles and the perianal, inguinal and axillary areas. After withdrawal 
of PB therapy, the skin lesions resolved completely within 2 weeks.
FigUre 1 | Dog P7 (mixed-breed, male-neutered, 8 years) developed 
a generalized, erosive-crusty dermatitis, especially in the face (a) and 
in the axiallry region (B) several weeks after initiation of PB; clear 
improvement of dermatologic signs after PB withdrawal.
7
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patients are listed in Table 5 (P1–P6) and are described below. 
All six dogs underwent complete dermatologic examination: 
ectoparasites were not found in any of these dogs but other possi-
ble causes for dermatologic signs such as food or environmentally 
induced atopic dermatitis could not be precluded assuredly. This 
fact has been regarded in ranking the probability of an adverse 
event using the Naranjo index.
One of the tested dogs (P1; possible ADR) showed a strong 
positive reaction in PT to the 10% petrolatum-solved PB 
(Figures 3A,B). The other patch test sites (negative control and 
5% dilution) as well as intradermal reactions were negative. 
This dog (P1, 8a) had been treated with PB for several years and 
developed a severe erosive perianal inflammation a few months 
after initiation of medical treatment with PB. After the positive 
PT, the AED therapy was changed to potassium bromide by first 
starting a loading dose of KBr (600 mg/kg per day, over 4 days) 
and subsequent gradual decrease of PB over a period of 2 weeks. 
Approximately 2 weeks after cessation of PB, a period of cluster 
seizures re-occurred, thus PB therapy was resumed. During the 
short period off PB, the perianal inflammation did not improve 
noticeably. It should be noted that this dog already had regular 
cluster seizures while being treated with PB.
Another dog (P3, possible ADR) was positive on IDT for 
PB, but negative on the patch test (Figures  4A,B). This dog 
was treated with PB for 3 years and showed pruritus and crusty 
lesions at the hind limbs and rhinarium. The cutaneous signs 
appeared shortly after PB therapy was started. PB therapy was 
not discontinued in this dog due to the severe cluster seizures 
seen in that patient.
A third dog (P5) had an ambiguous patch test result against the 
10% PB. This dog received PB only for 1 week. Therapy was then 
discontinued because of the sudden appearance of severe pruritus 
TaBle 6 | sensitivity, specificity, positive and negative predictive value of 
patch testing and intradermal testing for aeD hypersensitivity.
sensitivity  
(%)
specificity  
(%)
Positive 
predictive 
value (%)
negative 
predictive 
value (%)
Patch test 16.7 100.0 100.0 84.4
Intradermal skin test 16.7 100.0 100.0 84.4
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and alopecia at the limbs, crusty lesions periocular, at the ears 
and the inguinal region and erosive lesions with ulcera at the foot 
pads. After cessation of PB treatment, the skin lesions resolved 
completely within 2 weeks. This history supported a cutaneous 
adverse reaction to PB.
The other three tested dogs (P2, P4, and P6) with skin lesions 
developed under PB treatment were negative on IDT and PT.
None of the tested healthy laboratory beagle dogs showed a 
positive reaction on PT or IDT, neither did any of the private-
owned dogs of the negative control group (epileptic dogs under 
PB treatment without any registered cutaneous signs – currently 
or previously to AED therapy).
Sensitivity, specificity, and positive and negative predictive 
value of PT and IDT are listed in Table 6.
DiscUssiOn
This study was initiated based on our own unpublished clinical 
observations, which suggested simultaneous appearance of skin 
disease and epilepsy more commonly than previously reported. 
This prompted further investigations of the prevalence of cutane-
ous signs and their relationship to AED treatment. Subsequently, 
we confirmed a surprisingly high prevalence of cutaneous signs 
with 20% in the retrospective data analysis, and identified 15 dogs 
with potentially AED-caused cutaneous signs in the prospective 
study part. The prevalence in the prospectively evaluated group 
was 10.9% (15/137) and exceeded the prevalence of hepatopathy 
and pancreatitis in this investigation.
Dermatologic examination in our dogs was unable to delineate 
other etiologies than drug hypersensitivity, such as ectoparasite 
manifestations or allergies in all but one dog (P15), but not all 
diagnostic tests were applied to each dog (31). Literature describes 
a variety of cutaneous signs caused by an ADR, ranging from 
urticaria and angioedema (immediate drug hypersensitivity), 
pruritus, or exanthema to severe generalized syndromes such 
as lupoid/pemphigoid reactions or SND (15). March et al. retro-
spectively evaluated the appearance of SND/MEN with chronic 
PB administration in dogs (9). The two main differences between 
the results of this study and our results were the duration of AED 
treatment before onset of skin lesions (a median of 7  years in 
March’s study and weeks to months in our cases) and the sever-
ity of skin lesions (more severe and potentially life-threatening 
SND/MEN in March’s study versus predominantly mild to mod-
erate cutaneous signs in our study). March et  al. focused on a 
PB-induced hepatopathy, while we evaluated any reaction to the 
drug which may be the explanation for this difference.
In order to further highlight the relationship between AED treat-
ment and appearance of cutaneous signs the ADR probability scale of 
Naranjo et al. (26), a classification system validated in human medicine 
(32, 33), was applied. This scale estimates the likelihood of an ADR 
based on a number of criteria (Table 1). It is particularly helpful when 
proof of a drug reaction cannot be achieved under clinical circum-
stances with a drug challenge for ethical reasons, and also accounts for 
missing information on particular details, e.g., whether cutaneous signs 
were present prior to AED treatment. The individual patient history 
was reviewed with regard to the chronological relationship between 
initiation of drug treatment and appearance of dermatologic signs, the 
precise localization and appearance of skin lesions and whether signs 
improved after withdrawal of AED whenever feasible. Based on this 
evaluation, 2 of the 37 retrospective cases and 6 of the 15 prospective 
cases were classified as probably suffering from anticonvulsant drug 
hypersensitivity.
Another explanation for the high prevalence of dermatologic 
signs in epileptic dogs may be that there are common immunologic 
mechanisms underlying both the skin disease and the epilepsy. 
Several different facts support this hypothesis: food allergies or 
asthma might increase the risk of developing seizure disorders in 
humans and animals (34, 35). Mouse models show inflammatory 
pathways involved in allergic diseases that may also be activated 
in the brain and may cause epilepsy (36). Dietary supplementa-
tion with either ω3 fatty acids or medium chain triglycerides are 
used to improve seizure control in individuals with refractory 
epilepsy (37–41) and are also successfully administered to dogs 
with atopic dermatitis (42, 43). Thus, there may be a link between 
allergic diseases and epilepsy leading to cutaneous signs in epi-
leptic dogs independent of antiepileptic therapy. Investigations 
indicate that in humans, genetic factors predispose for developing 
an adverse reaction against AED (23). In contrast, in this study 
no breed predisposition for developing adverse events could be 
determined.
Secondary goal of our study was to evaluate PT and IDT as 
potential diagnostic methods in suspected ADRs against AEDs 
in dogs. In human, medicine PT is already frequently used to 
confirm AHS (44). In previous studies, the positive predictive 
value was much higher than the negative predictive value and 
the validity of the PT varied between the different AEDs (highest 
for carbamazepine, lowest for PB) (28). In contrast, in veterinary 
medicine, there are only few reports about the use of skin tests 
as diagnostic tools for ADRs. In 2008, Murayama described PT 
to identify an allergic reaction to ingredients of a shampoo in a 
miniature schnauzer (20, 45). Apart from this, PT proved use-
ful as an aid to choose the ingredients of an elimination diet in 
dogs with adverse food reaction (27), and IDT is widely used to 
identify offending environmental allergens in dogs with atopic 
dermatitis (30). Those established methods were used as guid-
ance to develop the skin tests in our study. Both tests showed a 
high negative predictive value, none of the healthy controls and 
none of the epileptic dogs under PB therapy without dermato-
logic signs showed a positive reaction in either PT or IDT. In 
the positive control group (n = 6), one of the tested dogs was 
positive on patch test, and one of the dogs showed a positive 
reaction on IDT. The contradictory results of PT and IDT in 
these two dogs might be due to different underlying immune 
mechanisms. An IDT evaluated shortly after injection as in this 
study is more sensitive for immediate hypersensitivity reactions, 
in contrast PT is more sensitive for delayed-type hypersensitivity 
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